Chief Scientific Officer
Wendy has 34 years of experience in drug discovery with over 15 years as a member of the P2Y12 antagonist project team in Astra/AstraZeneca. She designed, developed and implemented innovative test systems that were pivotal to the discovery and profiling of the anti-platelet agents Brilinta (ticagrelor) and Kengreal (cangrelor). Wendy joins us from a successful CRO, Xenogesis, where she was Director of Cell-Based Assay Development and managed a team of 13. Wendy brings to Platelet Services a deep knowledge of the drug discovery process and of tailoring test systems to the requirements of projects at various stages of the pipeline.